Clinical significance of autoantibody profiling and systemic inflammation in predicting outcomes of gastric cancer patients undergoing immunotherapy

doi:10.3748/wjg.v32.i17.117823

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 17

This Article

(36)

(40)

(0)

(1)

(688)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. May 7, 2026; 32(17): 117823
Published online May 7, 2026. doi: 10.3748/wjg.v32.i17.117823

Full Size Figure Download Figure

Figure 2 Kaplan-Meier analysis of progression-free survival based on autoantibody profiles. A-C: Progression-free survival curves are shown for patient groups categorized by antinuclear antibody (ANA) status (A), extractable nuclear antigen (ENA) status (B), and the combined positive autoantibody criterion (ANA or ENA) (C); D: Carcinoembryonic antigen levels using a cutoff of 35.48; E: Carbohydrate antigen 199 levels using a cutoff of 41.65; F: Neutrophil-to-lymphocyte ratio using a cutoff of 6.63; G: Platelet-to-lymphocyte ratio using a cutoff of 202; H: Pan-immune-inflammation value using a cutoff of 1256; I: Systemic immune-inflammation index using a cutoff of 1400. PFS: Progression-free survival; ANA: Antinuclear antibody; ENA: Extractable nuclear antigen; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; PIV: Pan-immune-inflammation value; SII: Systemic immune-inflammation index.

Citation: Zheng PM, Ouyang LB, Wang R, Jing KY, Gao HJ, Zhu CK. Clinical significance of autoantibody profiling and systemic inflammation in predicting outcomes of gastric cancer patients undergoing immunotherapy. World J Gastroenterol 2026; 32(17): 117823
URL: https://www.wjgnet.com/1007-9327/full/v32/i17/117823.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i17.117823

Zheng PM, Ouyang LB, Wang R, Jing KY, Gao HJ, Zhu CK. Clinical significance of autoantibody profiling and systemic inflammation in predicting outcomes of gastric cancer patients undergoing immunotherapy. World J Gastroenterol 2026; 32(17): 117823 [DOI: 10.3748/wjg.v32.i17.117823]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.